Skip to main content

Bausch Health Companies Inc. Value Stock - Dividend - Research Selection

Bausch health

ISIN: CA0717341071 , WKN: A2JQ1X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bausch Health: Solid Q3 Performance Reinforces Deleveraging Path

2025-11-11

Why Bausch Health Is A Buy After Rising 10% On Third-Quarter Results

2025-10-31
Discover why Bausch Health (BHC) is a top speculative buy after strong Q3 results, growth catalysts, and raised guidance.

Bausch Health Companies Inc. 2025 Q3 - Results - Earnings Call Presentation

2025-10-29

Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript

2025-10-29
Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDTCompany ParticipantsGaren Sarafian - VP & Head of Investor...

AllianceBernstein Global High Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE

2025-10-27
AllianceBernstein Global High Income Fund, Inc. [NYSE: AWF] (the "Fund") today released its monthly portfolio update as of September 30, 2025.

Bausch Health (BHC) Expected to Beat Earnings Estimates: Should You Buy?

2025-10-22
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assessing Bausch Health Companies (NYSE:BHC) Valuation After Recent Share Price Volatility

2025-10-12
Bausch Health Companies (NYSE:BHC) shares have seen some movement recently, with the stock dropping over 5% in the past day and roughly 17% for the month. This has investors watching closely to see if valuations might start to look more attractive. See our latest analysis for Bausch Health Companies. It’s been a volatile ride for Bausch Health Companies, with the share price recently sliding to $6.05 and notching a challenging 1-month share price return of -16.7%. Over the past year, total...

Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted

2025-10-10
Monopar Therapeutics stock has surged 2,000% with ALXN-1840's potential and promising MNPR-101-Zr data. Here's what investors need to know about MNPR.

Bausch Health Announces Results of Special Meeting of Shareholders

2025-10-09
LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7, 2025 (the "Shareholders Meeting"). At the Shareholders ...

George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil

2025-10-02
Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, with an established safety profileGeorge Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, as well as a futu